The quick read
CorMedix spent years burning cash without a dollar of product revenue. Then DefenCath launched, and the filed numbers flipped almost overnight: the fiscal year 2025 10-K shows $312 million in revenue and a 52% net margin, a transformation most pharmaceutical companies never achieve. The stock, meanwhile, is priced as though the turnaround is already unwinding. Management reaffirmed its 2026 revenue guidance on November 2 and reported a cash pile larger than most of its annual revenue. The open question is whether a real reimbursement cut in the middle quarters of 2026 explains the gap between that cash, that guidance, and a share price that has been cut in half.
Two numbers that should not sit next to each other
CorMedix closed November 3 at $5.39 per share. Its unaudited cash balance as of September 30, 2026, per the company’s November 2 business update, stood at roughly $355 million. At the share count reflected in our data, the cash balance per share exceeds the current trading price, a relationship the filed record can help contextualize alongside liabilities, burn rate, and revenue trajectory. A company sitting on more cash than its entire market value is a condition that analysts typically examine closely, the filed record surfaces the factors that bear on that reading.
To understand how CorMedix got here, picture a company that spent five consecutive years reporting zero commercial revenue while losing money at rates that would alarm anyone reading the filings. The fiscal year 2023 10-K captures the absurdity of that era in a single margin figure: spending was so far ahead of revenue that the loss-to-revenue ratio ran into the tens of thousands of percent, not because the business was uniquely reckless but because the denominator was nearly zero. DefenCath, a catheter-lock solution that reduces bloodstream infections in dialysis patients, finally reached commercial scale in 2024. The fiscal year 2024 10-K records the first real revenue: $43 million. A year later, the 2025 10-K shows $312 million. That is the movie. Now for the spreadsheet.
What the filings actually show
The most recent filed quarter is the one ended June 30, 2026, per the Q2 2026 10-Q. That filing records $101.9 million in consolidated revenue and a gross margin of 82.7%, meaning that for every dollar of sales, about 83 cents remained after the direct cost of making and delivering the product. That is an exceptionally high margin for a pharmaceutical company, and it reflects DefenCath’s pricing power inside the dialysis reimbursement system.
But compare Q2 to the quarter before it. The Q1 2026 10-Q shows $127.4 million in revenue. Revenue fell roughly 20% from Q1 to Q2, a sequential drop that is the central fact of the current story. DefenCath’s contribution shrank by more than $30 million in a single quarter. That decline in a single product over a single quarter is not noise. It is the reimbursement system doing exactly what it was designed to do.
The reimbursement question: what management said versus what CMS decided
DefenCath’s revenue is tied to a Medicare payment mechanism called the TDAPA, a temporary add-on payment that CMS (the Centers for Medicare and Medicaid Services, the federal agency that sets dialysis reimbursement rates) grants to new drugs while it gathers utilization data. Once that temporary period ends, CMS resets the add-on based on what it actually observed. For Q3 and Q4 2026, CMS set the DefenCath add-on at $2.37 per dialysis session. For Q1 2027, CMS has already finalized a rate of $8.32 per session, more than three times higher.
Management’s November 2 update reaffirmed full-year 2026 revenue guidance of $325 million to $345 million. Through the first two filed quarters, the company has recorded $229.3 million. That means the second half needs to deliver roughly $96 million to $116 million combined to hit the range. Given that Q3 carries the same depressed add-on rate as Q2, and Q2 came in just above $100 million, the math is tight but not implausible. The Q3 earnings release, scheduled for November 11, will be the first real test.
There is one complication management addressed directly. A large dialysis organization made public statements during its own investor call about the quarterly trajectory of DefenCath payments in 2027. CorMedix responded in its November 2 update by stating plainly that it had not provided that organization, or anyone else, with the utilization or pricing data needed to make such projections. The company told investors not to treat the dialysis organization’s numbers as CorMedix guidance. That is an unusual public correction, and it matters: it means third-party revenue models for 2027 may be built on data the company says it never shared.
The beat streak and the one miss
One way to test whether management’s words hold up is to look at the track record. According to MarketBeat’s earnings history, CorMedix has beaten analyst estimates in recent quarters, with the notable exception of Q4 2025, when earnings per share fell well short of the consensus estimate even as revenue came in roughly on target. That quarter’s EPS miss was large enough to suggest something below the revenue line, likely a one-time cost or accounting item, hit harder than expected. The filing record shows revenue guidance has been reliable; earnings-per-share guidance has been less so.
The Q3 2025 quarter is worth a moment. The Q3 2025 10-Q records $104.3 million in revenue against a consensus estimate of $65.6 million, a beat of nearly 60%. That was the quarter DefenCath’s commercial ramp collided with favorable reimbursement timing, and it prompted management to raise full-year 2025 guidance. The lesson from that quarter is that reimbursement rate changes can move revenue by tens of millions of dollars in a single period, in either direction.
The Melinta piece and the concentration risk
CorMedix is no longer a single-product company. The Melinta portfolio, a set of acquired antibiotics, contributed meaningfully alongside DefenCath in Q2 2026, and that diversification is real. But the concentration risk in the customer base is also real. The Q2 2026 10-Q notes that four customers each individually accounted for a double-digit share of Q2 revenue, and a single customer represented nearly half of gross accounts receivable at quarter-end. A company where one buyer holds nearly half the outstanding invoices is exposed to that buyer’s payment behavior in a way that a more fragmented customer base would not be.
What the math says about the mood
The math, meaning what the filed fundamentals show, describes a company that turned profitable in 2025, is generating cash at a rate that has pushed its balance to $355 million, and is guiding to full-year revenue that would represent roughly seven times what it earned as recently as 2024. The mood, meaning what the market is currently paying, prices the stock at a level that sits at the low end of the company’s own history. Those two readings are in sharp disagreement. The reimbursement step-down in the middle quarters of 2026 explains some of the gap. Whether it explains all of it is what the November 11 earnings release will begin to answer.
Reading the numbers
- $101.9 million, Q2 2026 revenue. What it is: total sales for the three months ended June 30, 2026, per the Q2 2026 10-Q. What it means here: revenue fell about 20% from the prior quarter, driven by a drop in DefenCath’s reimbursement add-on. In everyday terms: a shop that earned $127 in January through March earned $102 in April through June, not because fewer customers walked in, but because the price it was allowed to charge dropped.
- 82.7%, gross margin. What it is: the share of each revenue dollar left after the direct cost of producing and delivering the product. What it means here: CorMedix keeps about 83 cents of every dollar of sales before paying for sales staff, administration, or research. In everyday terms: a bakery that charges $10 for a loaf and spends $1.73 on flour, labor, and packaging keeps $8.27 to cover the rent and everything else.
- $8.32 versus $2.37, DefenCath add-on rates. What it is: the per-session Medicare payment CMS has set for Q1 2027 versus the rate in effect for Q3 and Q4 2026, per the November 2 business update. What it means here: the payment per treatment session more than triples from the current period to Q1 2027, which is the single largest variable in CorMedix’s near-term revenue. In everyday terms: a toll road that collected $2.37 per crossing this quarter will collect $8.32 per crossing starting in January, and the number of crossings determines the total.
- $355 million, cash as of September 30, 2026. What it is: unaudited cash and equivalents, reported in the November 2 business update. What it means here: the company holds cash roughly equal to its entire guided annual revenue, giving it a long runway even if revenue disappoints. In everyday terms: a household earning $40,000 a year that has $40,000 sitting in savings can absorb a bad year without borrowing.
- 47%, single-customer share of gross receivables. What it is: the portion of outstanding invoices owed by one customer as of June 30, 2026, per the Q2 2026 10-Q. What it means here: nearly half of what CorMedix is owed sits with one buyer, which is a concentration that amplifies any disruption in that relationship. In everyday terms: a contractor who has done seven jobs but is waiting on one client for nearly half the unpaid invoices is more exposed than the job count suggests.
Sources
- 10-Q for quarter ended June 30, 2026
- 10-Q for quarter ended March 31, 2026
- 10-K for fiscal year ended December 31, 2025
- 10-Q for quarter ended September 30, 2025
- 10-K for fiscal year ended December 31, 2024
- 10-K for fiscal year ended December 31, 2023
- CorMedix November 2, 2026 business update, GlobeNewswire
- CorMedix business update, BioSpace
- CorMedix earnings history, MarketBeat
- CorMedix guidance reaffirmation, StreetInsider
